Comparison of corneal thickness, anterior segment depth and pupil diameter between patients with neovascular age-related macular degeneration and controls

2009 ◽  
Vol 87 ◽  
pp. 0-0
Author(s):  
D PAHOR ◽  
N KNEZ ◽  
K SISKO
Keyword(s):  
Macular Degeneration ◽  
Pupil Diameter ◽  
Corneal Thickness ◽  
Anterior Segment ◽  
Age Related Macular Degeneration ◽  
Age Related

scholarly journals Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration

2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Beata Urban ◽  
Magdalena Szwabowicz ◽  
Alina Bakunowicz-Łazarczyk
Keyword(s):  
Macular Degeneration ◽  
Corneal Endothelium ◽  
Corneal Thickness ◽  
Age Related Macular Degeneration ◽  
Intravitreal Ranibizumab ◽  
Measuring Point ◽  
The Third ◽  
Cell Percentage ◽  
Age Related ◽  
The Mean

Purpose. To assess the effect of repeated intravitreal ranibizumab injections (RI) and aflibercept injections (AI) on the corneal endothelium and central corneal thickness (CCT) in patients with age-related macular degeneration (AMD). Materials and Methods. In the retrospective study, 110 eyes of 106 patients, aged 52 to 93 years, were analyzed. Fifty eyes were treated only with RI (I group), and 60 eyes were treated only with AI (II group). Every patient received one intravitreal injection of 0.5 mg of ranibizumab once a month or 2 mg of aflibercept for 3 subsequent months. Each patient received only 3 injections during the whole observation period. Corneal analysis was obtained with the specular microscope. Examinations were performed before initial treatment, after each injection, and 6 months after the first injection. Analysis included corneal endothelial cell density (ECD), hexagonal cell percentage (% Hex), coefficient of variation (CoV), and CCT. Results. There was a statistically significant ECD loss, regardless of the type of the anti-VEGF agent. The mean ECD value in the I group was 2397 ± 459 cells/mm2 before RI, 2389 ± 459 cells/mm2 after the first RI, 2386 ± 467 cells/mm2 after the second RI, 2378 ± 475 cells/mm2 after the third RI, and 2357 ± 460 cells/mm2 6 months after the first RI. The mean ECD value in the II group was 2448 ± 493 cells/mm2 before treatment, 2456 ± 498 cells/mm2 after the first AI, 2426 ± 496 cells/mm2 after the second AI, 2402 ± 488 cells/mm2 after the third AI, and 2348 ± 473 cells/mm2 6 months after the first AI. In comparison with the group treated with RI, the group treated with AI presented a greater ECD loss at each measuring point. The percentage of hexagonal cells was decreased in both groups. There was a slight increase in polymegathism in both treated groups. Ranibizumab proved to cause a small increase in CCT, while CCT remained unchanged in the aflibercept group. Conclusions. Repeated intravitreal injections of 0.5 mg of ranibizumab or 2 mg of aflibercept can influence the morphology of the corneal endothelium but not CCT.

Central Corneal Thickness in Patients With Neovascular Age-Related Macular Degeneration

Cornea ◽  
2007 ◽  
Vol 26 (2) ◽  
pp. 182-184 ◽  
Author(s):  
George D Kymionis ◽  
Theoni D Panagiotoglou ◽  
Sonia H Yoo ◽  
Nikolaos S Tsiklis ◽  
Emmanouel Christodoulakis ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Central Corneal Thickness ◽  
Corneal Thickness ◽  
Age Related Macular Degeneration ◽  
Age Related

Corneal Thickness of Eyes with Unilateral Age-Related Macular Degeneration

2014 ◽  
Vol 25 (3) ◽  
pp. 214-217
Author(s):  
Sedat Arikan ◽  
Ismail Ersan ◽  
Selcuk Kara ◽  
Baran Gencer ◽  
Safak Korkmaz ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Corneal Thickness ◽  
Age Related Macular Degeneration ◽  
Age Related

The efficacy of “IOL-Vip Revolution” telescopic intraocular lens in age-related macular degeneration cases with senile cataract

2018 ◽  
Vol 29 (6) ◽  
pp. 615-620
Author(s):  
Medine Yilmaz Dag ◽  
Filiz Afrashi ◽  
Serhad Nalcaci ◽  
Jale Mentes ◽  
Cezmi Akkin
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Intraocular Lens ◽  
Corneal Thickness ◽  
Anterior Chamber Depth ◽  
Age Related Macular Degeneration ◽  
Corrected Visual Acuity ◽  
Age Related ◽  
Best Corrected Visual Acuity

Purpose: To evaluate the efficacy of the IOL-Vip Revolution telescopic intraocular lens in age-related macular degeneration patients. Methods: A total of 13 eyes of 12 age-related macular degeneration patients with senile cataract were enrolled. Selection of the patients was done by means of a low vision diagnostic and rehabilitative program (IOL-Vip software) that evaluates residual visual function. After standard phacoemulsification surgery, the incision site was enlarged and the IOL-Vip Revolution system was implanted in the capsular bag. The outcome measures were best corrected visual acuity, contrast sensitivity, anterior chamber depth, endothelial cell density, central corneal thickness, and quality-of-life questionnaire. Results: The mean age of the subjects was 72.3 ± 8.5 years. The mean positive power of the intraocular lens was 59 ± 2 D and the negative intraocular lens power was standard (–46 D). Pre- and postoperative best corrected visual acuity were 1.08 ± 0.14 and 0.81 ± 0.16 logMAR in the operated eye and 1.13 ± 0.36 and 1.01 ± 0.40 logMAR in the unoperated eye, respectively. The best corrected visual acuity was increased significantly in both operated and unoperated eyes (p = 0.005 and 0.021, respectively). Quality of life and anterior chamber depth increased significantly (p = 0.018 and 0.008, respectively), while endothelial cell density decreased (p = 0.002). No significant differences were detected in central corneal thickness or contrast sensitivity (p = 0.133 and 0.684, respectively). Conclusion: The results showed that IOL-Vip Revolution telescopic intraocular lens is a promising treatment option in age-related macular degeneration patients. The rehabilitation program may have an important role in the restored clinical results, which also provided visual improvement in the unoperated eyes.

scholarly journals Clinical Experience with the Implantable Miniature Telescope for End-stage Age-related Macular Degeneration

2018 ◽  
Vol 11 (1) ◽  
pp. 51
Author(s):  
Aaleya Koreishi ◽  
Sumit Garg ◽  
◽  
Keyword(s):  
Clinical Trial ◽  
Macular Degeneration ◽  
Anterior Segment ◽  
Surgical Techniques ◽  
Clinical Trial Data ◽  
Trial Data ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
End Stage ◽  
Implantable Miniature Telescope

The implantable miniature telescope (IMT) is the first approved surgical treatment for visually impaired people with bilateral central vision loss due to end-stage age-related macular degeneration. The IMT – which is implanted unilaterally in the capsular bag following cataract extraction – provides 2.2x or 2.7x magnification of the central visual field. Clinical trial data suggest that the IMT can provide substantial and sustained improvements in best-corrected distance, near visual acuity, and patient quality of life metrics. These positive outcomes are heavily dependent on patient selection and screening, surgical technique, and postoperative rehabilitation, a treatment process that must be managed on an interdisciplinary basis over the course of 3–4 months. Here, we review the clinical trial data examining the safety and efficacy of the IMT, report our preliminary results with 13 real-world patients implanted with the commercial device (11 with follow-up data), define the key surgical techniques that contribute to optimal outcomes, and describe the anterior segment surgeon’s role in supporting both pre- and postoperative care. Nine eyes (82%) gained 4 or more lines of vision and two eyes (18%) did not gain any lines of vision.

scholarly journals Densitometric analysis of cornea in patients with neovascular age-related macular degeneration after intravitreal aflibercept loading dose

2020 ◽  
Vol 12 ◽  
pp. 251584142095085
Author(s):  
Cemile Ucgul Atilgan ◽  
Pinar Kosekahya ◽  
Dilara Ozkoyuncu Kocabas ◽  
Mustafa Koc ◽  
Yasin Sakir Goker
Keyword(s):  
Macular Degeneration ◽  
Anterior Segment ◽  
Corneal Topography ◽  
Age Related Macular Degeneration ◽  
Specular Microscopy ◽  
Loading Dose ◽  
Corneal Densitometry ◽  
Age Related ◽  
Intravitreal Aflibercept ◽  
Before And After

Purpose: To evaluate the anatomic changes in the cornea and anterior segment following intravitreal aflibercept loading dose for neovascular age-related macular degeneration. Methods: The study included 40 eyes of 40 patients with neovascular age-related macular degeneration. Each patient underwent a loading dose of one injection per month for three consecutive doses of aflibercept (0.05 ml/2 mg). Before and after the loading dose, a record was made for each patient of corneal topography, anterior segment, corneal densitometry, and lens densitometry parameters with the Pentacam HR and specular microscopy parameters with a non-contact specular microscope. The data before and after the aflibercept loading dose were compared. Results: Corneal densitometry parameters in the 0- to 2-mm and 2- to 6-mm concentric zones of the posterior layer were significantly higher after the loading dose compared with baseline ( p = 0.03, p = 0.04, respectively). Corneal densitometry parameters of the anterior, central, and total corneal layer in the 10- to 12-mm concentric zone were also significantly higher after the loading dose compared with baseline ( p = 0.009, p = 0.02, and p = 0.007, respectively). No significant changes were determined in respect of corneal topography, anterior segment, lens densitometry, and specular microscopy parameters ( p > 0.05 for all). Conclusion: The aflibercept loading dose caused slightly increased densitometric values in some corneal regions while it did not affect the corneal topography, anterior segment, lens densitometry, and specular microscopy parameters.

Long-term outcomes of ranibizumab treatment in neovascular age-related macular degeneration

2020 ◽  
Vol 1 (2) ◽  
pp. 102-107
Author(s):  
Burak Simsek ◽  
◽  
Isilay Ozsoy Koyun ◽  
Sevil Ari Yaylali ◽  
◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Anterior Segment ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Group 3 ◽  
The Difference ◽  
Group 2 ◽  
Number Of Injections ◽  
Group 1

AIM: To investigate 3-year results in our neovascular age related macular degeneration (NV-AMD) patients treated with ranibizumab. METHODS: Retrospective study. Visual acuity (VA), a full biomicroscopic examination (anterior segment and fundus), and optical coherence tomography (OCT) findings were noted at every visit. All patients were followed monthly. The VA values for the visits closest to 12, 24, and 36mo were analysed. 101 eyes of 73 patients were enrolled. According to the initial VA, the patients were divided three groups: initial VA ≤35 (Group 1), 36-54 (Group 2), and ≥55 letters (Group 3). After three loading doses of 0.5 mg ranibizumab if retreatment was needed, again, 0.5 mg ranibizumab was administered RESULTS: Totally 57 of the 101 eyes were from males and 44 were from females. The average age was 75.1 years. The difference on the changes of VA among three groups at 24 and 36mo were statistically significant (P=0.02 and 0.001 respectively). At the end of the 36-month follow-up the VA increase in Group 2 was significant (P=0.001). At the 12, 24, and 36mo visits most of the eyes showed no VA loss and most of these eyes were in Group 1. The average number of injections administered was 7.3 and the average number of visits was 23.9 during the follow-up. CONCLUSION: VA improvement was significant in those with mild initial VA (36-54 letters). Most eyes showed no VA loss regardless of the initial VA. No correlation between the final VA and the average number of injections.

Age related macular degeneration (ARMD) – pathophysiological and clinical features and therapeutic concepts

2001 ◽  
Vol 58 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Ursula Körner-Stiefbold
Keyword(s):  
Macular Degeneration ◽  
Clinical Features ◽  
Altersbedingte Makuladegeneration ◽  
Age Related Macular Degeneration ◽  
Genetische Faktoren ◽  
Age Related ◽  
Therapeutic Concepts

Die altersbedingte Makuladegeneration (AMD) ist eine der häufigsten Ursachen für einen irreversiblen Visusverlust bei Patienten über 65 Jahre. Nahezu 30% der über 75-Jährigen sind von einer AMD betroffen. Trotz neuer Erkenntnisse in der Grundlagenforschung ist die Ätiologie, zu der auch genetische Faktoren gehören, noch nicht völlig geklärt. Aus diesem Grund sind die Behandlungsmöglichkeiten zum jetzigen Zeitpunkt noch limitiert, so dass man lediglich von Therapieansätzen sprechen kann. Die derzeit zur Verfügung stehenden Möglichkeiten wie medikamentöse, chirurgische und laser- und strahlentherapeutische Maßnahmen werden beschrieben.

Sign in / Sign up

Export Citation Format

Share Document